This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60…
Looking for participants aged 18 to 55 who have trouble with heroin or other opiates to participate in a month-long research study at Columbia University Irving Medical Center evaluating the relationship between brain tasks and memory.